104 related articles for article (PubMed ID: 24649766)
21. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study.
Marks LS; Gittelman MC; Hill LA; Volinn W; Hoel G
Urology; 2009 Dec; 74(6):1318-22. PubMed ID: 19815265
[TBL] [Abstract][Full Text] [Related]
22. New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.
Yoshida M; Kudoh J; Homma Y; Kawabe K
Int J Urol; 2012 Apr; 19(4):306-16. PubMed ID: 22251148
[TBL] [Abstract][Full Text] [Related]
23. What are the factors contributing to failure in improvement of subjective symptoms following silodosin administration in patients with benign prostatic hyperplasia? Investigation using a pressure-flow study.
Matsukawa Y; Hattori R; Sassa N; Yamamoto T; Gotoh M
Neurourol Urodyn; 2013 Mar; 32(3):266-70. PubMed ID: 22907775
[TBL] [Abstract][Full Text] [Related]
24. [Results of open multicenter study of the safety of doxazosin in combination with indigal in men with stages I-II prostatic adenoma].
Pavlov VN; Komiakov BK; Grigor'ev MÉ; Sivkov AV; Bliumberg BI; Kazikhinoruv AA; Izmaĭlov AA; Boiarko AV; Abzalilov RA
Urologiia; 2013; (2):42-4, 46. PubMed ID: 23789362
[TBL] [Abstract][Full Text] [Related]
25. [Multi-center trial on the early effects of silodosin on lower urinary tract symptoms associated with benign prostatic hyperplasia].
Ogawa T; Uemura H; Sano F; Hoshino K; Kita K; Hayashi N; Kagota M; Murakami T; Makiyama K; Miyoshii Y; Nakaigawa N; Yao M; Shimura H; Furuhata A; Fujikawa N; Shioi K; Ueki T; Hara Y; Saitou K; Kawakami S; Satomi Y; Hattori Y; Teranishi J; Kondo K; Kishida T; Saito K; Noguchi K; Fuji H; Yamaguchi T; Kinoshita Y; Nomura S; Yoshida M; Sakai N; Terao H; Matsumoto T; Umemoto S; Ogo Y; Kobayashi K; Noguchi S; Asakura T; Kohdaira T; Iguchi K; Izumi K; Hirano M; Kanno H; Takahashi T; Nukui F; Mokuo Y; Muraoka K; Osada Y; Funahashi M; Kitami K; Sugiura S; Ohta J; Miura T; Ishibashi Y; Masuda M; Komiya A; Suwa Y; Hashiba T; Mitaka K; Kobayashi M; Ohsaka K; Futoshi T; Tsuchiya T; Iwasaki A; Yamashita Y; Matsuzaki J; Kubota Y
Hinyokika Kiyo; 2008 Dec; 54(12):757-64. PubMed ID: 19174997
[TBL] [Abstract][Full Text] [Related]
26. Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia.
Sakata K; Morita T
BMC Urol; 2012 Oct; 12():29. PubMed ID: 23082785
[TBL] [Abstract][Full Text] [Related]
27. Effects of silodosin and tamsulosin on the urethra and cardiovascular system in young and old dogs with benign prostatic hyperplasia.
Kobayashi S; Tomiyama Y; Tatemichi S; Hoyano Y; Kobayashi M; Yamazaki Y
Eur J Pharmacol; 2009 Jun; 613(1-3):135-40. PubMed ID: 19389393
[TBL] [Abstract][Full Text] [Related]
28. [Silodosin treatment of patients with prostatic adenoma].
Govorov AV; Pushkar' DIu
Urologiia; 2012; (3):71-4. PubMed ID: 23074941
[No Abstract] [Full Text] [Related]
29. [Profile of silodosin].
Montorsi F
Urologiia; 2013; (2):112-4, 116-7. PubMed ID: 23789376
[TBL] [Abstract][Full Text] [Related]
30. [Clinical and urodynamic evaluation of efficacy of conservative treatment of urination disorders in patients with benign prostate hyperplasia].
Danilov VV; Danilova TI; Danilov VV; Danilov VV
Urologiia; 2013; (5):55-8. PubMed ID: 24437242
[TBL] [Abstract][Full Text] [Related]
31. Silodosin: erectile and ejaculatory disorders.
Prescrire Int; 2012 May; 21(127):129. PubMed ID: 22844684
[No Abstract] [Full Text] [Related]
32. The efficacy and safety of silodosin for the treatment of ureteral stones: a systematic review and meta-analysis.
Yang D; Wu J; Yuan H; Cui Y
BMC Urol; 2016 May; 16(1):23. PubMed ID: 27233621
[TBL] [Abstract][Full Text] [Related]
33. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability.
Lepor H; Hill LA
Pharmacotherapy; 2010 Dec; 30(12):1303-12. PubMed ID: 21114397
[TBL] [Abstract][Full Text] [Related]
34. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Gratzke P; Kirby RS
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
J Urol; 2013 Jan; 189(1 Suppl):S117-21. PubMed ID: 23234615
[TBL] [Abstract][Full Text] [Related]
36. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
[TBL] [Abstract][Full Text] [Related]
37. [Medical treatment of prostatic adenoma. Urinary flow data].
Giglio V; Campo B; Motta M
Minerva Urol; 1972; 24(3):104-7. PubMed ID: 4141047
[No Abstract] [Full Text] [Related]
38. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
Lukacs B; Leplège A; Thibault P; Jardin A
Urology; 1996 Nov; 48(5):731-40. PubMed ID: 8911517
[TBL] [Abstract][Full Text] [Related]
39. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia.
Tatemichi S; Tomiyama Y; Maruyama I; Kobayashi S; Kobayashi K; Maezawa A; Kobayashi M; Yamazaki Y; Shibata N
Neurourol Urodyn; 2006; 25(7):792-9; discussion 800-1. PubMed ID: 16894620
[TBL] [Abstract][Full Text] [Related]
40. [Tadenan treatment of prostatic adenoma].
Danilov VV; Elisseva EV; Vasil'chenko AV
Urologiia; 2009; (2):68, 70-3. PubMed ID: 19526878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
